Each year about the time the daffodils are revealing their cheery yellow blossoms in the Mid-Atlantic region, we’re readying our annual cover story on the top 10 research findings in wound care for the printer.
This year again proved to be a bountiful year for wound care research — and we’re not talking about garden-variety findings either.
Robert Kirsner, M.D., Ph.D., Skin & Aging editorial board member as well as Section Editor for our sister journal Wounds, from which we highlight the top research from 2006, has made his top 10 selections of the wound care research most relevant to dermatology.
This year’s article focuses on interesting topics, including the following:
- Are silver dressings really the gold standard for healing infected wounds?
- Does the amino acid homocysteine hinder wound healing?
- Do leg ulcers often go undiagnosed?
- What progress has been made in the care of keloids?
- Why are lasers actually harmful — not helpful, as previously thought — to the wound-healing process.
You can read about these studies and others, accompanied by expert comments from Dr. Kirsner, in this month’s cover article beginning on page 58.
Focus on Psoriasis
The biologic therapies have been on the market for treatment of psoriasis since the first one — alefacept (Amevive) — was approved in January 2003. Since then, unarguably, an avalanche of research evaluating efficacy, safety and more has been available to report on these therapies for the treatment of psoriasis and psoriatic arthritis.
But the biologics are not the only story. New topicals for treating psoriasis are being studied along with combination therapies and new protocols for tried-and-true treatments. There is also research on devices used to treat psoriasis. Not only that, but there are analyses of the cost-effectiveness of different therapies and the psychological impact of this disease.
With so much ground to cover, this month we are debuting a new column, “Psoriasis Reports.” This frequent column will highlight new research into the diagnosis and treatment of psoriasis and psoriatic arthritis.
Senior Editor Ellen Meyer will not only offer a close look at the research data, but she will also offer a fresh perspective on it through interviews with the doctors who performed the research.
This month, she focuses on a poster presentation from the recent AAD meeting in Washington D.C., detailing a Phase IV study on the use of efalizumab (Raptiva) for treating psoriasis of the hands and feet. Highlights of the data along with excerpts from an interview with the poster’s lead author, Craig Leonardi, M.D., combine to give a more in-depth look at the study’s results as well as insight into the study of hand and foot psoriasis.
Please turn to page 56 to read the new column.
Larisa Hubbs
Executive Editor
lhubbs@hmpcommunications.com
Each year about the time the daffodils are revealing their cheery yellow blossoms in the Mid-Atlantic region, we’re readying our annual cover story on the top 10 research findings in wound care for the printer.
This year again proved to be a bountiful year for wound care research — and we’re not talking about garden-variety findings either.
Robert Kirsner, M.D., Ph.D., Skin & Aging editorial board member as well as Section Editor for our sister journal Wounds, from which we highlight the top research from 2006, has made his top 10 selections of the wound care research most relevant to dermatology.
This year’s article focuses on interesting topics, including the following:
- Are silver dressings really the gold standard for healing infected wounds?
- Does the amino acid homocysteine hinder wound healing?
- Do leg ulcers often go undiagnosed?
- What progress has been made in the care of keloids?
- Why are lasers actually harmful — not helpful, as previously thought — to the wound-healing process.
You can read about these studies and others, accompanied by expert comments from Dr. Kirsner, in this month’s cover article beginning on page 58.
Focus on Psoriasis
The biologic therapies have been on the market for treatment of psoriasis since the first one — alefacept (Amevive) — was approved in January 2003. Since then, unarguably, an avalanche of research evaluating efficacy, safety and more has been available to report on these therapies for the treatment of psoriasis and psoriatic arthritis.
But the biologics are not the only story. New topicals for treating psoriasis are being studied along with combination therapies and new protocols for tried-and-true treatments. There is also research on devices used to treat psoriasis. Not only that, but there are analyses of the cost-effectiveness of different therapies and the psychological impact of this disease.
With so much ground to cover, this month we are debuting a new column, “Psoriasis Reports.” This frequent column will highlight new research into the diagnosis and treatment of psoriasis and psoriatic arthritis.
Senior Editor Ellen Meyer will not only offer a close look at the research data, but she will also offer a fresh perspective on it through interviews with the doctors who performed the research.
This month, she focuses on a poster presentation from the recent AAD meeting in Washington D.C., detailing a Phase IV study on the use of efalizumab (Raptiva) for treating psoriasis of the hands and feet. Highlights of the data along with excerpts from an interview with the poster’s lead author, Craig Leonardi, M.D., combine to give a more in-depth look at the study’s results as well as insight into the study of hand and foot psoriasis.
Please turn to page 56 to read the new column.
Larisa Hubbs
Executive Editor
lhubbs@hmpcommunications.com
Each year about the time the daffodils are revealing their cheery yellow blossoms in the Mid-Atlantic region, we’re readying our annual cover story on the top 10 research findings in wound care for the printer.
This year again proved to be a bountiful year for wound care research — and we’re not talking about garden-variety findings either.
Robert Kirsner, M.D., Ph.D., Skin & Aging editorial board member as well as Section Editor for our sister journal Wounds, from which we highlight the top research from 2006, has made his top 10 selections of the wound care research most relevant to dermatology.
This year’s article focuses on interesting topics, including the following:
- Are silver dressings really the gold standard for healing infected wounds?
- Does the amino acid homocysteine hinder wound healing?
- Do leg ulcers often go undiagnosed?
- What progress has been made in the care of keloids?
- Why are lasers actually harmful — not helpful, as previously thought — to the wound-healing process.
You can read about these studies and others, accompanied by expert comments from Dr. Kirsner, in this month’s cover article beginning on page 58.
Focus on Psoriasis
The biologic therapies have been on the market for treatment of psoriasis since the first one — alefacept (Amevive) — was approved in January 2003. Since then, unarguably, an avalanche of research evaluating efficacy, safety and more has been available to report on these therapies for the treatment of psoriasis and psoriatic arthritis.
But the biologics are not the only story. New topicals for treating psoriasis are being studied along with combination therapies and new protocols for tried-and-true treatments. There is also research on devices used to treat psoriasis. Not only that, but there are analyses of the cost-effectiveness of different therapies and the psychological impact of this disease.
With so much ground to cover, this month we are debuting a new column, “Psoriasis Reports.” This frequent column will highlight new research into the diagnosis and treatment of psoriasis and psoriatic arthritis.
Senior Editor Ellen Meyer will not only offer a close look at the research data, but she will also offer a fresh perspective on it through interviews with the doctors who performed the research.
This month, she focuses on a poster presentation from the recent AAD meeting in Washington D.C., detailing a Phase IV study on the use of efalizumab (Raptiva) for treating psoriasis of the hands and feet. Highlights of the data along with excerpts from an interview with the poster’s lead author, Craig Leonardi, M.D., combine to give a more in-depth look at the study’s results as well as insight into the study of hand and foot psoriasis.
Please turn to page 56 to read the new column.
Larisa Hubbs
Executive Editor
lhubbs@hmpcommunications.com
